: Akero's results showed the potential for cirrhosis reversal, which temporarily overshadowed Madrigal's market position.
Madrigal continues to report positive results from its own clinical trials, including the trial. MadrigalВ Dip
The consensus among firms like TipRanks is that Madrigal’s treatment could become a "blockbuster," supported by its first-mover advantage in the space. : Akero's results showed the potential for cirrhosis
: Experts believe the U.S. market has approximately 1.5 million diagnosed MASH patients, providing "plenty of room" for multiple treatments, including Madrigal’s Rezdiffra. Clinical & Operational Status : Experts believe the U
: Evercore ISI explicitly labeled the dip as a Buying Opportunity , maintaining an "Outperform" rating with a price target of $392 .
: Analysts at Piper Sandler recently raised their price target for Madrigal to $400 (up from $336), viewing the competitor data as validation for the entire MASH treatment market rather than a threat.